# Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

> **NCT06968195** · PHASE1 · SUSPENDED · sponsor: **Roswell Park Cancer Institute** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
- Recurrent Hepatocellular Carcinoma
- Refractory Hepatocellular Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8

## Interventions

- **BIOLOGICAL:** Anti-GPC3-CAR Autologous T Lymphocytes
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Fludarabine
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan

## Key facts

- **NCT ID:** NCT06968195
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-05-01
- **Primary completion:** 2028-05-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 24 (ESTIMATED)
- **Why stopped:** awaiting agreement with Sponsor
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06968195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06968195, "Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06968195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*